10-K: Digipath Inc. Announces Asset Sale and Strategic Shift in Annual 10-K Filing

Digipath Inc. reports the planned sale of its cannabis testing lab and a strategic shift towards acquiring a new business in its annual 10-K filing.

Summary

• Digipath Inc. has filed its annual report on Form 10-K for the fiscal year ended September 30, 2023.
• The company is in the process of selling substantially all of the assets of its cannabis testing laboratory subsidiary, Digipath Labs, Inc., for $2.3 million in cash, subject to adjustments.
• The sale is contingent upon approval from the Nevada Cannabis Compliance Board (CCB), expected by June 30, 2024, with a potential closing as early as January 2024.
• Following the asset sale, Digipath intends to acquire another business but has not yet begun the search for candidates.
• A Management Services Agreement is in place with the buyer to manage the lab operations, with Digipath receiving 15% of cash collections (minimum $15,000) plus 55% of any remaining cash after expenses and a $10,000 monthly management fee to the buyer.
• The company's financial statements for the year ended September 30, 2023, show a net income of $246,775, which includes a net loss from continuing operations of $681,655 and a net income from discontinued operations of $928,429.
• As of September 30, 2023, Digipath had current assets of $765,798 and current liabilities of $3,121,814, resulting in a working capital deficit of $2,356,016.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient cash reserves.
• Digipath's common stock is traded on the OTCQB under the symbol DIGP, with a closing price of $0.04 as of January 12, 2024.
• The company has 87,096,820 shares of common stock outstanding as of January 16, 2024.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a going concern warning from the auditor and a substantial working capital deficit. While there is a strategic shift with the asset sale, the overall outlook is concerning due to the company's financial instability and dependence on future capital raises.

Positives

• The sale of the cannabis testing lab will provide Digipath with $2.3 million in cash, subject to adjustments.
• The company reported a net income of $246,775 for the fiscal year ended September 30, 2023, driven by a gain from discontinued operations.
• The management services agreement provides a continuing revenue stream for Digipath while the lab is under new management.
• The company is actively seeking to acquire a new business, indicating a strategic shift towards growth.

Negatives

• The company has a significant working capital deficit of $2,356,016.
• The auditor has expressed substantial doubt about the company's ability to continue as a going concern.
• The sale of the lab is contingent upon regulatory approval, which may not be obtained.
• The company has not yet commenced a search for a new business to acquire, creating uncertainty about future operations.
• The company has incurred recurring losses from operations.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and achieving sustainable revenues.
• The sale of the cannabis testing lab is subject to regulatory approval, which may be delayed or denied.
• The company's future success depends on its ability to identify and acquire a suitable new business.
• The company faces competition in the cannabis testing market and may struggle to attract and retain customers.
• Changes in federal and state regulations regarding cannabis could negatively impact the company's business.
• The company has a history of losses and may not become profitable.
• The company's stock is a penny stock and may be subject to significant price fluctuations and limited trading activity.

Future Outlook

The company intends to acquire another business after the sale of its cannabis testing lab, but has not yet commenced a search for candidates. The company's future is dependent on its ability to raise additional capital and achieve sustainable revenues and profitable operations.

Management Comments

• Management believes that the transaction may close as early as January 2024.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

The cannabis industry is rapidly evolving with increasing legalization and a growing market for testing services. Digipath's strategic shift reflects the need to adapt to changing market conditions and capitalize on new opportunities. The company's decision to sell its lab and seek a new business indicates a move away from direct testing operations and towards a potentially more diversified business model.

Comparison to Industry Standards

• The cannabis testing market is expected to reach approximately $2.5 billion in 2025, with an estimated CAGR of 11.9% from 2017-2025, according to The Insight Partners.
• Digipath's decision to sell its lab and seek a new business is a departure from the typical growth strategy of other cannabis testing companies, such as Steep Hill, which focuses on expanding its testing facilities and services.
• While companies like Eurofins and SGS have established themselves as major players in the broader testing market, Digipath's focus on the cannabis industry makes it a more specialized player.
• The company's financial performance, with a net income of $246,775 for the year ended September 30, 2023, is not directly comparable to larger, more established companies in the testing industry, which typically report significantly higher revenues and profits.
• Digipath's working capital deficit and auditor's concerns about its ability to continue as a going concern are significant challenges that are not typically seen in more financially stable companies in the industry.

Related Party Transactions

• During the year ended September 30, 2023 the Company incurred compensation expense of $ 60,000 for services provided by its CFO and paid its CFO $ 111,437 for accrued compensation related to services provided in prior periods.
• During the year ended September 30, 2023 the Company incurred fees of $ 34,000 for services provided by its directors and paid its directors $ 30,000 for services provided, and its directors waived the payment of $ 138,000 that had been accrued for services provided.
• During the year ended September 30, 2023, the Company granted 3,400,000 and 1,400,000 shares of its common stock to the officers and directors as compensation for services performed with a fair value of $ 24,820 and $ 9,860 , respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the uncertainty surrounding its future operations.
• Employees may be affected by the sale of the cannabis testing lab and the company's strategic shift.
• Customers of the cannabis testing lab will be impacted by the change in ownership and management.
• Creditors face increased risk due to the company's financial challenges and going concern warning.

Next Steps

• The company will seek approval from the Nevada Cannabis Compliance Board (CCB) for the sale of its cannabis testing lab.
• The company will begin the search for a new business to acquire after the sale of its lab.
• The company will need to secure additional financing to continue operations.

Key Dates

Keywords

cannabis testing, asset sale, strategic acquisition, Digipath Labs, financial results, going concern, convertible notes, preferred stock, OTCBB, OTCQB